Total Payments
$903,698
2024 Payments
$5,302
Companies
36
Transactions
294
Medicare Patients
585
Medicare Billing
$158,740
Payment Breakdown by Category
Research$899,316 (99.5%)
Food & Beverage$4,135 (0.5%)
Travel$208.01 (0.0%)
Education$38.69 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $899,316 | 49 | 99.5% |
| Food and Beverage | $4,135 | 242 | 0.5% |
| Travel and Lodging | $208.01 | 1 | 0.0% |
| Education | $38.69 | 2 | 0.0% |
Payments by Type
Research
$899,316
49 transactions
General
$4,382
245 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $523,845 | 44 | $0 (2018) |
| Eli Lilly and Company | $373,810 | 2 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | 2 | $0 (2019) |
| ALK-Abello, Inc | $661.13 | 3 | $0 (2018) |
| GlaxoSmithKline, LLC. | $594.98 | 45 | $0 (2019) |
| United Therapeutics Corporation | $348.61 | 10 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $341.20 | 20 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $309.23 | 20 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $299.70 | 21 | $0 (2019) |
| Actelion Pharmaceuticals US, Inc. | $278.81 | 16 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,302 | 3 | Eli Lilly and Company ($5,252) |
| 2023 | $368,596 | 3 | Eli Lilly and Company ($368,558) |
| 2021 | $17.34 | 1 | Resmed Corp ($17.34) |
| 2020 | $17.03 | 1 | Mylan Specialty L.P. ($17.03) |
| 2019 | $2,140 | 43 | Takeda Pharmaceuticals U.S.A., Inc. ($1,500) |
| 2018 | $37,098 | 111 | Glenmark Pharmaceuticals Inc. ($35,160) |
| 2017 | $490,528 | 132 | Glenmark Pharmaceuticals Inc. ($488,685) |
All Payment Transactions
294 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,252.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 04/29/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/07/2024 | Getinge USA Sales, LLC | Cardiohelp (Device) | Food and Beverage | In-kind items and services | $32.79 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/05/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $15.72 | General |
| Category: HFCWO | ||||||
| 05/23/2023 | Body Vision Medical Inc. | LungVision (Device) | Food and Beverage | Cash or cash equivalent | $22.61 | General |
| Category: Interventional Pulmonology | ||||||
| 02/21/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $368,558.00 | Research |
| 09/23/2021 | Resmed Corp | AirSense (Device) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Sleep | ||||||
| 10/21/2020 | Mylan Specialty L.P. | Yupelri (Drug), Perforomist | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Respiratory and Allergy | ||||||
| 11/13/2019 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: RESPIRATORY | ||||||
| 10/08/2019 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $10.14 | General |
| Category: RESPIRATORY | ||||||
| 10/04/2019 | Philips Electronics North America Corporation | inCourage (Device) | Food and Beverage | Cash or cash equivalent | $19.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/27/2019 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $8.20 | General |
| Category: RESPIRATORY | ||||||
| 09/06/2019 | Philips Electronics North America Corporation | inCourage (Device) | Food and Beverage | Cash or cash equivalent | $20.17 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/15/2019 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $18.10 | General |
| Category: HFCWO | ||||||
| 05/08/2019 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $10.65 | General |
| Category: RESPIRATORY | ||||||
| 05/08/2019 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $6.65 | General |
| Category: RESPIRATORY | ||||||
| 05/08/2019 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $2.27 | General |
| Category: RESPIRATORY | ||||||
| 04/09/2019 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: Respiratory | ||||||
| 04/05/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/03/2019 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $11.82 | General |
| Category: RESPIRATORY | ||||||
| 04/02/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: RESPIRATORY | ||||||
| 04/01/2019 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Immunology | ||||||
| 03/27/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: RESPIRATORY | ||||||
| 03/26/2019 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: Respiratory | ||||||
| 03/25/2019 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: Cardiology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP304-201 | Glenmark Pharmaceuticals Inc. | $488,685 | 41 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Glenmark Pharmaceuticals Inc. | $35,160 | 3 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $5,252 | 1 |
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | 2 |
| MT-11 | ALK-Abello, Inc | $161.12 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 30 | 56 | $45,194 | $9,190 |
| 2022 | 3 | 142 | 274 | $171,197 | $36,066 |
| 2021 | 3 | 190 | 387 | $254,691 | $56,691 |
| 2020 | 5 | 223 | 393 | $216,145 | $56,794 |
Total Patients
585
Total Services
1,110
Medicare Billing
$158,740
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 30 | 56 | $45,194 | $9,190 | 20.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 86 | 167 | $142,325 | $28,202 | 19.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 44 | 85 | $24,664 | $6,654 | 27.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 22 | $4,208 | $1,210 | 28.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 133 | 284 | $230,745 | $48,886 | 21.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 41 | 85 | $20,873 | $6,802 | 32.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 18 | $3,073 | $1,003 | 32.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 133 | 265 | $182,439 | $47,330 | 25.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 38 | 55 | $14,069 | $4,489 | 31.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 29 | 48 | $8,356 | $2,714 | 32.5% |
| 31500 | Emergent insertion of breathing tube into windpipe cartilage using an endoscope | Facility | 2020 | 12 | 12 | $4,181 | $1,372 | 32.8% |
| 36556 | Insertion of central venous catheter for infusion, patient 5 years or older | Facility | 2020 | 11 | 13 | $7,101 | $889.15 | 12.5% |
About Dr. Chandar Abboy, M.D
Dr. Chandar Abboy, M.D is a Critical Care Medicine healthcare provider based in Fayetteville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275583585.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chandar Abboy, M.D has received a total of $903,698 in payments from pharmaceutical and medical device companies, with $5,302 received in 2024. These payments were reported across 294 transactions from 36 companies. The most common payment nature is "" ($899,316).
As a Medicare-enrolled provider, Abboy has provided services to 585 Medicare beneficiaries, totaling 1,110 services with total Medicare billing of $158,740. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Pulmonary Disease
- Location Fayetteville, NC
- Active Since 05/10/2006
- Last Updated 06/09/2025
- Taxonomy Code 207RC0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1275583585
Products in Payments
- Uloric (Drug) $1,500
- Odactra (Biological) $500.01
- ORENITRAM (Drug) $348.61
- SYMBICORT (Drug) $223.52
- TRELEGY ELLIPTA (Drug) $219.41
- OPSUMIT MACITENTAN (Drug) $202.82
- LONHALA MAGNAIR (Drug) $202.66
- Dust mite (D. farinae) (Biological) $161.12
- OFEV (Drug) $160.89
- Xolair (Biological) $153.79
- Prolastin-C (Biological) $145.30
- NUCALA (Biological) $136.52
- SMARTVEST (Device) $128.98
- ANORO (Drug) $119.87
- STIOLTO RESPIMAT (Drug) $109.61
- BREO (Drug) $106.04
- ZERBAXA (Drug) $87.29
- Adempas (Drug) $81.77
- FASENRA (Drug) $80.03
- Dymista (Drug) $66.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Fayetteville
Dr. Edward Jackson, M.d, M.D
Critical Care Medicine — Payments: $9,963
Critical Care Medicine $9,963
Juan Gaitan Rueda, Md, MD
Critical Care Medicine — Payments: $4,944
Critical Care Medicine $4,944
Ryan James, Md, MD
Critical Care Medicine — Payments: $4,856
Critical Care Medicine $4,856
Dr. Ikemefula Ekekwe, Md, MD
Critical Care Medicine — Payments: $4,651
Critical Care Medicine $4,651
Leonel Carrasco Abinader, M.d, M.D
Critical Care Medicine — Payments: $4,465
Critical Care Medicine $4,465
Lindsey Barnes, Md, MD
Critical Care Medicine — Payments: $3,893
Critical Care Medicine $3,893